Revlon targeted by class action
This article was originally published in The Rose Sheet
Executive Summary
Class action filed by Berger & Montague, P.C. would include all shareholders who participated in Revlon's exchange offer of Sept. 24, 2009, converting shares of Class A common stock for preferred stock. Following that transaction, Revlon posted "stellar" financial results for its fiscal 2009 third quarter, ended Sept. 30, "causing the company's Class A common stock price to rise by over 300%," according to Berger & Montague's recent release. Stockholders were not apprised of company's expected positive results, though they were entitled to such information before deciding whether to exchange stock, the law firm says. Investors interested in acting as lead plaintiff in the suit are encouraged to contact Berger & Montague, whose office of approximately 70 attorneys "[has] recovered several billion dollars for consumers and investors" as a "pioneer in class action litigation." Revlon's controlling stockholders MacAndrews & Forbes Holdings Inc. proposed to buy out minority stakeholders in spring 2009 (1"The Rose Sheet" April 27, 2009)
You may also be interested in...
Revlon buyout proposal
MacAndrews & Forbes Holdings, which owns 75% of Revlon's stock, has proposed to buy out minority shareholders, the cosmetics firm reports April 20. Under the terms of the proposal, all outstanding shares of Revlon's Class A common stock not held by MacAndrews & Forbes or its affiliates would be converted into $75 mil. worth of preferred shares (approximately 20 mil. shares at $3.74 per share). The stock would be redeemed after four years and would pay an annual cash dividend of $12.5%. In exchange MacAndrews & Forbes would forgive $75 mil. of a $107 mil. loan to Revlon's wholly-owned subsidiary Revlon Consumer Products Corp, and extend the loan's maturity to 2013. Revlon's board of directors is reviewing the deal
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.